09.12.2015 08:00:00 CET

Nexstim Plc's Financial Information in 2016

Helsinki, 9th December 2015 at 9:00 am

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, will publish the following financial information in 2016:

- The 2015 Financial Statements Release and Half-Yearly Report July-December 2015 (H2) on Monday, February 29, 2016

- Half-Yearly Report January-June 2016 (H1) on Wednesday, August 17, 2016

Nexstim's Annual Report 2015 will be published on the Company's website on Wednesday, March 9, 2016.

The Annual General Meeting is tentatively scheduled to be held on Thursday, March 31, 2016 at 12:00 noon.


Janne Huhtala, CEO

For further information please visit www.nexstim.com or contact:

Nexstim                                                                 +358 (0)40 8615046

Janne Huhtala, Chief Executive Officer   janne.huhtala@nexstim.com

UB Securities Ltd (Certified Adviser)                 +358 (0)9 2538 0246

Consilium Strategic Communications             +44 (0)20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Laura Thornton   nexstim@consilium-comms.com

About Nexstim Plc

Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBTŪ). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBTŪ and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. In H2 2015, the Company received a recommendation from the Data Safety Monitoring Board (DSMB) to continue the Phase III stroke therapy NICHE trial without any modifications. The first interim analysis on the NICHE (Navigated Inhibitory rTMS to Contralesional Hemisphere) trial using NBTŪ was performed after 81 patients reached their primary safety outcome assessment, on track, at six months post-treatment. For more information please visit www.nexstim.com.

Nexstim Plc's Financial Information in 2016